Dr Alan Cohen joins MAP Pharmaceuticals
This article was originally published in Scrip
Executive Summary
Dr Alan Cohen has joined MAP Pharmaceuticals(US) as vice-president of clinical development and medical affairs, pulmonary. He will oversee development and execution of the company's paediatric asthma clinical programme, including Phase III trials for Unit Dose Budesonide. Dr Cohen has more than 20 years' therapeutic, clinical and medical experience and most recently served as chief medical officer and vice-president of global medical affairs, safety and pharmacovigilance at Jazz Pharmaceuticals.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.